The Investor
26 Aug 2026, 15:12
Argenx Gains 2.7% as UBS Upgrades Stock to Buy and Wells Fargo Raises Price Target
Argenx (NASDAQ: ARGX) shares rose about 2.7% after receiving two positive analyst actions, strengthening sentiment toward the biotechnology company.
UBS upgraded Argenx from Neutral to Buy and set a $1,400 price target. Based on the $1,047.31 current share price, the target implies roughly 34% upside.
Wells Fargo also became more bullish on the stock. Analyst Derek Archila maintained an Overweight rating while raising the firm's price target from $1,350 to $1,415, implying approximately 35% upside from the referenced share price.
Analyst Optimism Supports ARGX
The simultaneous positive actions from two major investment banks provide a likely catalyst for today's gain. UBS's move is particularly notable because it represents an outright rating upgrade rather than simply a higher valuation target.
Argenx operates in the biotechnology sector and is focused on treatments for severe autoimmune diseases. Its commercial portfolio is centered on its FcRn-targeting franchise, giving the company exposure to a growing class of immunology therapies.
The rating report provided does not include the analysts' detailed reasoning, so the specific assumptions behind the upgrades cannot be determined from the report alone. Still, the combination of UBS moving to Buy and Wells Fargo lifting its already-bullish target reinforces positive analyst sentiment around Argenx's growth prospects.
With both firms now assigning targets around $1,400 or higher, the analyst actions appear to be a key factor behind ARGX's 2.7% gain.
Argenx (NASDAQ: ARGX) shares rose about 2.7% after receiving two positive analyst actions, strengthening sentiment toward the biotechnology company.
UBS upgraded Argenx from Neutral to Buy and set a $1,400 price target. Based on the $1,047.31 current share price, the target implies roughly 34% upside.
Wells Fargo also became more bullish on the stock. Analyst Derek Archila maintained an Overweight rating while raising the firm's price target from $1,350 to $1,415, implying approximately 35% upside from the referenced share price.
Analyst Optimism Supports ARGX
The simultaneous positive actions from two major investment banks provide a likely catalyst for today's gain. UBS's move is particularly notable because it represents an outright rating upgrade rather than simply a higher valuation target.
Argenx operates in the biotechnology sector and is focused on treatments for severe autoimmune diseases. Its commercial portfolio is centered on its FcRn-targeting franchise, giving the company exposure to a growing class of immunology therapies.
The rating report provided does not include the analysts' detailed reasoning, so the specific assumptions behind the upgrades cannot be determined from the report alone. Still, the combination of UBS moving to Buy and Wells Fargo lifting its already-bullish target reinforces positive analyst sentiment around Argenx's growth prospects.
With both firms now assigning targets around $1,400 or higher, the analyst actions appear to be a key factor behind ARGX's 2.7% gain.
